Quarterly report [Sections 13 or 15(d)]

Segments

v3.26.1
Segments
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Segments

Note 11—Segments

 

The Company has two reportable segments. The legacy segment focuses on the previous endeavors of TNF Pharmaceuticals, Inc. This business segment operates in the clinical-stage pharmaceutical space and is specifically focused on Isomyosamine (formerly MYMD-1). The second and primary segment is focused on the development and eventual application of quantum computing technology, both for cryptocurrency applications and beyond. The Company’s chief operating decision maker (“CODM”), who is responsible for evaluating financial performance and allocating resources, is the Executive Chairman of the Board. The accounting policies of the duel segments are the same as those described in the summary of significant accounting policies. The CODM does not use assets to assess the segment. The CODM assesses performance for each segment and decides how to allocate resources based on net operating loss excluding stock-based compensation and warrant issuance expenses. The CODM uses a non-GAAP measure, net of operating loss excluding stock-based compensation and warrant issuance expenses, as the primary measure of operating performance and to monitor the Company’s cash burn and adherence to budget.

 

To date, the Company has not generated any product revenues and has incurred losses and negative cash flows from operations since inception.

 

The following table presents certain financial data for the Company’s two reportable segments and a reconciliation to the Company’s consolidated net loss.

 

Schedule of Reconciliation Consolidated Net Loss  

    2026     2025     2026     2025  
    Pharmaceuticals     Computing Technology  
    2026     2025     2026     2025  
Sales     -       -       -       -  
Product Cost of Sales     -       -       -       -  
Gross Profit     -       -       -       -  
                                 
Operating Expenses                                
Administrative Expenses     106,665       841,685       959,985       -  
Research and Development Expenses     18,948       1,545,513       491,586       -  
Stock Based Compensation     -       84,636       58,606       -  
Franchise Tax Expense     21,940       -       197,463       -  
Warrant Issuance Expense     -       -       -       -  
Segment Net Loss     147,553       2,471,834       1,707,640       -  
                                 
Reconcilement of Net Loss                                
Adjustments and Reconciling Items                                
Dividends Paid on Series H Preferred Stock     -       -       -       -  
Interest and Dividend Income     -       62,512       71,340       -  
Gain (Loss) on Sales of Marketable Securities     -       2,176       11,782       -  
Unrealized Gain (Loss) on Marketable Securities     -       (1,597 )     19,294       -  
Change in Fair Value of Derivative Liabilities     -       1,284,000       510,000       -  
Loss on FMV of Contingent Compensation     -       -       -       -  
Casualty Gain/(Loss)     -       -       -       -  
Total Adjustments and Reconciling Items     -       1,347,091       612,416       -  
                                 
Consolidated Net Loss     (147,553 )     (1,124,743 )     (1,095,224 )     -  

 

Segment assets are not reviewed by the CODM and, accordingly, asset information is not presented.